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Abstract
Background: Dimebon is an antihistamine compound with a long history of clinical use in Russia.
Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders. It has
demonstrated efficacy in phase II Alzheimer's disease (AD) and Huntington's disease (HD) clinical
trials. The mechanisms responsible for the beneficial actions of Dimebon in AD and HD remain
unclear. It has been suggested that Dimebon may act by blocking NMDA receptors or voltage-
gated Ca2+ channels and by preventing mitochondrial permeability pore transition.
Results: We evaluated the effects of Dimebon in experiments with primary striatal neuronal
cultures (MSN) from wild type (WT) mice and YAC128 HD transgenic mice. We found that
Dimebon acts as an inhibitor of NMDA receptors (IC50 = 10 μM) and voltage-gated calcium
channels (IC50 = 50 μM) in WT and YAC128 MSN. We further found that application of 50 μM
Dimebon stabilized glutamate-induced Ca2+ signals in YAC128 MSN and protected cultured
YAC128 MSN from glutamate-induced apoptosis. Lower concentrations of Dimebon (5 μM and 10
μM) did not stabilize glutamate-induced Ca2+ signals and did not exert neuroprotective effects in
experiments with YAC128 MSN. Evaluation of Dimebon against a set of biochemical targets
indicated that Dimebon inhibits α-Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine H1 and
H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors with high affinity. Dimebon also had
significant effect on a number of additional receptors.
Conclusion: Our results suggest that Ca2+ and mitochondria stabilizing effects may, in part, be
responsible for beneficial clinical effects of Dimebon. However, the high concentrations of
Dimebon required to achieve Ca2+ stabilizing and neuroprotective effects in our in vitro studies (50
μM) indicate that properties of Dimebon as cognitive enhancer are most likely due to potent
inhibition of H1 histamine receptors. It is also possible that Dimebon acts on novel high affinity
targets not present in cultured MSN preparation. Unbiased evaluation of Dimebon against a set of
biochemical targets indicated that Dimebon efficiently inhibited a number of additional receptors.
Potential interactions with these receptors need to be considered in interpretation of results
obtained with Dimebon in clinical trials.
Background
Huntington disease (HD) is an inherited, incurable, auto-
somal dominant disease caused by the expansion of CAG
trinucleotide repeats in the first exon of the huntingtin
gene [1,2]. It is characterized by progressive neurodegen-
eration resulting in motor abnormalities including chorea
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and psychiatric disturbance with gradual dementia. HD is
fatal and causes death within 15–20 years of the onset of
the symptoms. The mutant huntingtin (Htt) with
expanded polyglutamine (polyQ) is widely expressed in
the brain and peripheral tissues but causes selective and
most prominent loss of medium spiny neurons in stria-
tum (MSN) which leads to the major clinical abnormali-
ties that characterize the disease. The exact cause of
neuronal loss in HD remains unknown [3]. Recent evi-
dence indicates that dysregulation of glutamate and Ca2+
(calcium) signaling in MSN play an important role in HD
pathogenesis [4]. The "Ca2+ hypothesis of HD" suggests
that Ca2+  signaling inhibitors may have a therapeutic
value for treatment of HD [4]. Abnormal neuronal Ca2+
signaling has also been proposed to play an important
role in Alzheimer's disease [5,6].
Dimebon is a drug that has been developed and used as
an antihistamine in Russia since 1983. Recently, Dime-
bon has been proposed to be useful for treating neurode-
generative disorders [7]. Dimebon demonstrated
significant positive effects in six-month randomized, dou-
ble-blinded, placebo-controlled phase II trial of 183
patients with mild to moderate Alzheimer's disease (AD)
conducted by Medivation [8]. The phase III trial of Dime-
bon in AD will soon be initiated. Dimebon also demon-
strated efficacy in phase 2 trial of patients with
Huntington's disease (HD) conducted by Medivation and
Huntington Study Group (DIMOND). Despite extremely
encouraging results in clinical trials, the mechanisms
responsible for beneficial actions of Dimebon in AD and
HD remain poorly understood. Previous reports sug-
gested that Dimebon may act as an inhibitor of NMDA
receptors [9], voltage-gated Ca2+ channels [10] or as a
blocker of mitochondrial permeability transition pore
[11]. These potential targets indicated that Dimebon may
act by stabilizing neuronal Ca2+ signaling, which may
explain clinical benefits observed in HD and AD trials. In
the present study, we evaluated the ability of Dimebon to
inhibit NMDA receptors and voltage-gated Ca2+ channels
in cultured MSN from wild type mice and from the
YAC128 HD transgenic mice model. We also evaluated
neuroprotective effects of Dimebon in previously devel-
oped glutamate-toxicity assay with cultured YAC128 MSN
[12]. We concluded that Ca2+ and the mitochondria stabi-
lizing effects of Dimebon may only in part be responsible
for beneficial effects in human clinical trials and addi-
tional mechanisms of Dimebon's actions need to be
uncovered to explain its beneficial clinical actions in HD
and AD trials.
Methods
Drugs
The Glutamate was from Tocris; and the Fura-2/AM was
purchased from Sigma. Dimebon (2,3,4,5-Tetrahydro-
2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-
pyrido(4,3-b)indole, C21H25N3, CAS 3613-73-8) was syn-
thesized by Nanosyn Inc. The synthesized material was
97.3% pure by HPLC-UV275 analysis. The structure of
Dimebon (Fig 1) was independently confirmed by mass-
spectroscopy and 1D and 2D NMR analysis (Bruker 500
NMR spectrometer). The proton and carbon 1D NMR
spectra of the Dimebon sample used in our experiments
are provided as Additional Files 1 and 2. In our experi-
ments, Dimebon was dissolved in DMSO as concentrated
stock (100 mM) and further diluted to its final concentra-
tion in Neurobasal-A medium for in vitro HD assay, in
extracellular recording solutions for electrophysiology
experiments or in artificial cerebrospinal fluid (ACSF) for
Ca2+ imaging experiments.
Chemical structure of Dimebon Figure 1
Chemical structure of Dimebon. Chemical structure of 
2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyri-
dyl)ethyl)-1H-pyrido(4,3-b)indole (CAS 3613-73-8)Molecular Neurodegeneration 2008, 3:15 http://www.molecularneurodegeneration.com/content/3/1/15
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Primary neuronal cultures
YAC128 mice (FVBN/NJ background strain) were
obtained from Jackson Labs (stock number 004938). The
male YAC128 mice were crossed to wild type (WT) female
FVBN/NJ mice and P1-P2 pups were collected and geno-
typed by PCR. The primary cultures of striatal medium
spiny neurons (MSN) were established from YAC128 and
control wild type pups as we previously described [12-15].
Striata were dissected, diced and digested with trypsin.
After dissociation, neurons were plated on poly-L-lysine
(Sigma) coated 12 mm round coverslips (Assistent) in
Neurobasal-A medium supplemented with 2% B27, 1
mM glutamine and penicillin-streptomycin (all from Inv-
itrogen) and kept at 37°C in a 5% CO2 environment.
Calcium imaging experiments
Ca2+ imaging experiments with 13–14 DIV (days in vitro)
MSN cultures were performed as previously described
[12,14-16], using a DeltaRAM illuminator, an IC-300
camera, and IMAGEMASTER PRO software (all from PTI).
The MSN were loaded with 5 μM fura-2 AM (Molecular
Probes) for 45 min at 37°C in artificial cerebrospinal fluid
(ACSF, containing the following: 140 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, pH7.3).
Coverslips were mounted onto a recording/perfusion
chamber (RC-26G, Warner Instruments) and positioned
on the movable stage of an Olympus (Melville) IX-70
inverted microscope. The cells were maintained in ACSF
at 37°C during experiments (PH1 heater, Warner Instru-
ments). Images at 340 and 380 nm excitation wavelengths
were acquired every 6 s and shown as 340/380 image
ratios. Baseline (1–3 min) measurements were obtained
before first pulse of glutamate. The 20 μM glutamate solu-
tion was dissolved in ACSF and 1-min pulses of 37°C
glutamate solution (SH-27B in-line solution heater,
Warner Instruments) were applied by using a valve con-
troller (VC-6, Warner Instruments) driven by a square-
pulse electrical wave-form generator (Model 148A,
Wavetek). 10 μM or 50 μM Dimebon was dissolved in
ACSF or 20 μM glutamate solution for the Dimebon
application.
Electrophysiology for NMDAR and voltage-gated Ca2+ 
channels
Whole-cell patch-clamp recordings of NMDAR activity
were performed with cultured MSN from WT and YAC128
mice at DIV9-10 as we previously described [15]. Medium
spiny neurons were distinguished based on morphologi-
cal identification and membrane capacitance ranging
from 4–10 pF. A multi-barrel perfusion system was
employed to achieve a rapid exchange of extracellular
solutions as we previously described [15]. All drugs were
prepared according to the specifications of the manufac-
turers and applied with a gravity-fed "sewer pipe" capil-
lary array. Whole-cell currents were recorded using
Axopatch 200B amplifiers (Axon Instruments). Data were
filtered at 2 kHz and digitized at 5 Hz using a Digidata
1200 DAC unit (Axon Instruments). The online acquisi-
tion was done using pCLAMP software (Version 8, Axon
Instruments). Cultured MSN were held at VH = -60 mV
membrane potential. Standard extracellular solutions
contained 140 mM NaCl, 5 mM KCl, 2.0 mM CaCl2, 10
mM HEPES (pH 7.4; 310 mOsm). The pipette solution
contained 135 mM CsMeSO4, 10 mM HEPES, 5 mM 1,2-
bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, 3
mM MgATP, 1 mM MgCl2, 0.3 mM GTP-tris. In all exper-
iments, 50 μM glycine was added to both control and
NMDA-containing extracellular solutions. 10 μM CNQX
and 0.1 μM TTX were added to the extracellular recording
solution immediately before each experiment to block
AMPA/kainate-type glutamate receptors and voltage-gated
sodium currents, respectively.
Whole-cell patch-clamp recordings of voltage gated Ca2+
currents in cultured MSN at DIV9 were performed accord-
ing to the published procedures [17]. The recording cham-
ber was perfused with extracellular solution containing
140 mM TEA-Cl, 10 mM BaCl2, 10 mM HEPES, 20 mM
glucose, 0.001 mM tetrodotoxin (TTX), pH 7.4, with TEA-
OH, 310 mOsm. The pipette solution contained 110 mM
CsCl, 10 mM EGTA, 4 mM ATP-Mg, 0.3 mM GTP-Na, 25
mM HEPES, 10 mM Tris-phosphocreatine, 20 units/ml
creatine phosphokinase, pH 7.3, with CsOH, 290 mOsm.
Ba2+ current traces were corrected for linear capacitive leak
with online P/6 trace subtraction. MSN were voltage
clamped at -80 mV, and test pulses were applied at 10 s
intervals.
In vitro HD assay
The in vitro HD assay with wild type and YAC128 MSN
cultures was conduced as previously described [12,13].
Dimebon was added to the 14 DIV MSN at the final con-
centration of 5 μM, 10 μM or 50 μM. After 30 minutes
incubation with Dimebon, the MSN were exposed for 7 h
to 250 μM glutamate in Neurobasal-A added to the cul-
ture medium. During exposure to glutamate, the cells
were maintained in a cell culture incubator (humidified
5% CO2, 37°C). Immediately after the treatment with
glutamate, neurons were fixed for 30 min in 4% parafor-
maldehyde plus 4% sucrose in PBS (pH7.4), permeabi-
lized for 5 min in 0.25% Triton-X-100, and stained by
using the DeadEnd fluorometric TUNEL System
(Promega). Nuclei were counterstained with 5 μM propid-
ium iodine (PI) (Molecular Probes). Coverslips were
extensively washed with PBS and mounted in Mowiol 4–
88 (Polysciences). For quantification, six to eight ran-
domly chosen microscopic fields containing 100–300
MSN each were cell-counted for YAC128 and wild type
cultures. The number of TUNEL-positive neuronal nuclei
was calculated as a fraction of PI-positive neuronal nucleiMolecular Neurodegeneration 2008, 3:15 http://www.molecularneurodegeneration.com/content/3/1/15
Page 4 of 11
(page number not for citation purposes)
in each microscopic field. The fractions of TUNEL-positive
nuclei determined for each microscopic field were aver-
aged and the results are presented as means ± SE (n =
number of fields counted).
Evaluation against biochemical targets
The activity of Dimebon against selected set of biochemi-
cal targets was performed by MDS Pharma Services http:/
/discovery.mdsps.com/. The Dimebon was provided to
MDS Pharma as dry powder, dissolved in DMSO and
tested in 10 μM concentrations. The standard Lead Profil-
ing + CYP450 screen was performed according to MDS
Pharma specifications with additional custom-chosen tar-
gets added to the screen as indicated.
Statistical analysis
All experiments were repeated at least three times. Data
were evaluated for statistical significance by analysis using
SigmaPlot t-test or One-Way ANOVA. Statistical differ-
ence was considered to be significant if p < 0.05.
Results
Dimebon inhibits glutamate-induced Ca2+ increase in 
YAC128 MSN
To test the postulated "Ca2+ stabilizing" effects of Dime-
bon, in the first series of experiments, we compared Ca2+
responses induced by glutamate application to wild type
(WT) and YAC128 MSN at 13–14 DIV. In our previous
studies, we found that repetitive pulses of 20 μM gluta-
mate resulted in a bigger elevation of cytosolic Ca2+ levels
in the YAC128 MSN compared with that in WT MSN
[12,14,15]. To test effects of Dimebon on glutamate-
induced Ca2+ signals, we applied 20 pulses of 20 μM gluta-
mate (each pulse 1 min in duration, followed by a 1 min
washout) in the presence of 10 μM or 50 μM Dimebon.
Control experiments were performed in the absence of
Dimebon. The intracellular Ca2+  concentration in the
experiments was continuously monitored by Fura-2 imag-
ing and the 340/380 ratio was used to quantitatively
determine the concentration of the intracellular Ca2+
([Ca2+]i). The increase in Ca2+ was calculated as a differ-
ence between basal values of Ca2+ prior to glutamate
application and at completion of "20 glutamate pulses"
protocol in the same cell. On average, the increase in Ca2+
was 0.250 ± 0.029 for WT MSN and 0.403 ± 0.046 for
YAC128 MSN (Figs 2A, B, G). Thus, in agreement with our
previous findings [12,14,15], the increase in Ca2+ was sig-
nificantly higher in YAC128 MSN than in WT MSN. In the
presence of 10 μM Dimebon, the increase in Ca2+ was
0.236 ± 0.021 for WT MSN and 0.461 ± 0.034 for YAC128
MSN (Figs 2C, D, G). Thus, incubation with 10 μM Dime-
bon had no significant effect on the glutamate-induced
Ca2+ increase in WT or YAC128 MSN. In the presence of
50 μM Dimebon, the increase in Ca2+ was 0.290 ± 0.027
for WT MSN and 0.234 ± 0.022 for YAC128 MSN (Figs 2E,
F, G). Thus, 50 μM Dimebon significantly reduced the
glutamate-induced Ca2+ increase of YAC128 MSN without
affecting the Ca2+ signals in WT MSN. These results indi-
cate that Dimebon exerts "Ca2+  stabilizing" effects in
YAC128 MSN at 50 μM but not at 10 μM concentration.
NMDAR inhibition by Dimebon
Previous reports suggested that Dimebon may act as an
inhibitor of NMDA receptors [9]. In the next series of
experiments, we evaluated the ability of Dimebon to
block NMDA-activated currents in DIV9-10 WT and
YAC128 MSN cultures. The MSN were voltage-clamped at
-60 mV and the currents were evoked by local and rapid
application of 100 μM NMDA using multi-barrel per-
fusion system ("sewer pipe"). Consistent with previous
findings [15], we found that NMDA induced much larger
currents in YAC128 MSNs than in the WT littermate cul-
tures (Fig 3A). Application of 1 μM, 10 μM, or 50 μM of
Dimebon caused a significant reduction in the size of
NMDA-induced currents in both WT and YAC128 MSN
(Fig 3A). The inhibitory effects of Dimebon were reversi-
ble and the size of NMDA currents quickly recovered fol-
lowing a washout of Dimebon (data not shown). To
compare results from different experiments, we normal-
ized the peak amplitude of NMDA-evoked currents to the
amplitude recorded in the absence of Dimebon in the
same cell and averaged normalized data from multiple
experiments (from at least 4 independent cultures estab-
lished from YAC128 and WT). Analysis of obtained results
suggested that Dimebon blocks NMDAR-currents in WT
and YAC128 MSN with IC50 = 10 μM (Fig 3B). The
YAC128 MSN have increased contribution of NR2B sub-
type of NMDAR when compared to WT MSN [15,18]. Our
results suggest that Dimebon does not display selectivity
for NR2B subtype of NMDAR, as both WT and YAC128
MSN currents were inhibited with similar potency (Fig
3B). In general, our results are consistent with previous
studies of Dimebon's inhibitory effects on NMDAR [9].
Voltage-gated calcium channel inhibition by Dimebon
High voltage-activated Ca2+ channels have been proposed
to be another target of Dimebon [10]. In the next series of
experiments, we evaluated effects of Dimebon on high
voltage-activated Ca2+ currents recorded in wild type (WT)
and YAC128 MSN cultures at DIV9-10. Whole-cell patch-
clamp recordings of currents in cultured MSN were per-
formed according to the published procedures [17] using
10 mM Ba2+ as a current carrier. The MSN were voltage
clamped at -80 mV, and test pulses to 0 mV were applied
at 10 s intervals. Consecutive application of 1 μM, 10 μM,
and 50 μM of Dimebon resulted in a progressive reduc-
tion in the size of depolarization-evoked currents (Fig
4A). To compare results from different experiments, we
normalized the peak size of voltage-gated Ca2+ currents to
the amplitude recorded in the absence of Dimebon in theMolecular Neurodegeneration 2008, 3:15 http://www.molecularneurodegeneration.com/content/3/1/15
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Effects of Dimebon on glutamate-induced Ca2+signals Figure 2
Effects of Dimebon on glutamate-induced Ca2+signals. (A-B), Repetitive application of 20 μM glutamate induces Ca2+ 
signals in MSN from the WT (A) and YAC128 (B) mice. (C-D), The same experiment as in (A) and (B) was performed in the 
presence of 10 μM Dimebon with WT (C) and YAC128 (D) MSN. (E-F), The same experiment as in (A) and (B) was performed 
in the presence of 50 μM Dimebon with WT (E) and YAC128 (F) MSN. The traces shown on panels (A-F) are average traces 
from all MSN for each experimental group. (G) The average increase of basal Ca2+ level (mean ± SE, n is the number of MSN 
analyzed) after 20 pulses of glutamate are shown for WT MSN (n = 16), YAC128 MSN (n = 21), WT MSN in the presence of 
10 μM Dimebon (n = 44), YAC128 MSN in the presence of 10 μM Dimebon (n = 41), WT MSN in the presence of 50 μM 
Dimebon (n = 17) and YAC128 MSN in the presence of 50 μM Dimebon (n = 44).
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same cell and averaged normalized data from multiple
experiments (from at least 4 independent cultures estab-
lished from YAC128 and WT). Analysis of obtained results
suggested that Dimebon blocks high-voltage activated
Ca2+ channels in WT and YAC128 MSN with IC50 = 50
μM (Fig 4B). Dimebon demonstrated similar potency in
WT and YAC128 MSN cultures (Fig 4B). In general, our
results are consistent with previous studies of Dimebon's
inhibitory effects on high voltage-activated Ca2+ channels
[10].
Neuroprotective effects of Dimebon in in vitro HD assay
To evaluate neuroprotective effects of Dimebon, we per-
formed a series of glutamate toxicity experiments with WT
and YAC128 MSN DIV14 cultures. In the absence of gluta-
mate approximately 5–10% of neurons are apoptotic in
both wild type (WT) and YAC128 MSN cultures. Follow-
ing exposure to 250 μM glutamate, the fraction of apop-
totic WT MSN is increased to 25–40% and the fraction of
apoptotic YAC128 MSN is increased to 55–70% (Table 1).
The difference between the glutamate-induced apoptosis
Effects of Dimebon on NMDA-evoked currents Figure 3
Effects of Dimebon on NMDA-evoked currents. (A) Representative traces of NMDA-evoked current recorded from 
DIV9-10 WT and YAC128 MSN. The white bar represents application of 100 μM NMDA in the presence of 50 μM glycine and 
black bar represents application of 1 μM, 10 μM and 50 μM Dimebon as indicated. (B) Dose-dependence of Dimebon block. 
The peak NMDA-induced currents were normalized to the peak NMDA-induced currents in the same cell in the absence of 
Dimebon. The normalized data at each Dimebon concentration were averaged from several experiments and shown as mean 
± SE (n = 8 for WT and n = 9 for YAC128 MSN). The IC50 = 10 μM for WT and YAC128 MSN.
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of YAC128 and WT MSN is highly significant and consti-
tutes a quantitative basis for the in vitro HD assay we have
previously described [12,13,15]. The neuroprotective
effects of Dimebon were evaluated at 5 μM, 10 μM and 50
μM concentrations using the in vitro HD assay (Table 1,
Fig 5). In these experiments, Dimebon was added 30 min-
utes prior to the exposure of MSN cultures to glutamate.
We found that 5 μM and 10 μM Dimebon had no signifi-
cant effects on the glutamate-induced apoptosis of
YAC128 MSN (Table 1, Figs 5A, B). At 50 μM concentra-
tion, Dimebon showed significant protective effects in the
in vitro HD assay (Table 1, Fig 5C).
Evaluation of Dimebon against a set of biochemical 
targets
To further understand potential mechanisms responsible
for clinical effects of Dimebon, we evaluated Dimebon
against a set of selected biochemical targets. Dimebon
evaluation was performed by MDS Pharma Services http:/
/discovery.mdsps.com/. The standard Lead Profiling +
CYP450 screen was performed with additional custom-
selected targets added to the screen. The results of the
screen obtained at 10 μM of Dimebon are provided as
Additional File 3. The significant effect (> 50% inhibition)
by 10 μM of Dimebon in binding or biochemical experi-
Effects of Dimebon on voltage-gated calcium currents Figure 4
Effects of Dimebon on voltage-gated calcium currents. (A) Representative traces of voltage-gated Ca2+ currents 
evoked by membrane depolarization from -80 mV holding potential to 0 mV in DIV9 WT and YAC128 MSN. The current 
waveforms recorded in the same cell in the absence of Dimebon (open circle), and in the presence of 1 μM (filled circle), 10 
μM (open triangle) and 50 μM (filled diamond) of Dimebon are shown. (B) Dose-dependence of Dimebon block of voltage-
gated Ca2+ channels. The peak voltage-gated Ca2+ currents were normalized to the peak voltage-gated Ca2+ currents recorded 
in the same cell in the absence of Dimebon. The normalized data at each Dimebon concentration were averaged from several 
experiments and shown as mean ± SE (n = 14 for WT and n = 15 forYAC128 MSN). The IC50 = 50 μM for WT and YAC128 
MSN.
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Evaluation of Dimebon in in vitro HD assay Figure 5
Evaluation of Dimebon in in vitro HD assay. Glutamate-induced apoptosis of WT and YAC128 MSN treated with Dime-
bon at different concentrations. WT and YAC128 MSN at 14 DIV were exposed to 250 μM glutamate for 7 h, fixed, permea-
bilized and analyzed by TUNEL staining and PI counterstaining. The Dimebon was added 30 min before the application of 
glutamate. The fraction of TUNEL-positive is plotted against glutamate concentration for WT (open circle) and YAC128 (YAC, 
filled circles) mice. The data are shown as mean ± SE (n = 6–8 microscopic fields, 100–300 MSN per field). The results in the 
absence (black symbols) and presence (red symbols) obtained in the presence of 5 μM of Dimebon (A) 10 μM Dimebon (B) 
and 50 μM Dimebon (C) are compared.
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ments was observed for a set of receptors listed on Fig 6. It
is apparent that Dimebon very efficiently inhibits α-
Adrenergic receptors (α1A, α1B, α1D, and α2A), Histamine
H1 and H2 receptors and Serotonin 5-HT2c, 5-HT5A, 5-
HT6receptors (Fig 6). For all of these receptors 10 μM of
Dimebon resulted in > 90% inhibition. Dimebon also sig-
nificantly inhibited Dopamine D1, D2S, D3 receptors, Imi-
dazoline I2  receptor, Serotonin 5-HT2  and 5-HT2B
receptors (70–80% inhibition). Low affinity (50–60%
inhibition) interactions were also observed for CYP450,
2C19 receptor, voltage-gated L-type Ca2+  channel,
Dopamine D4.2 receptor, and Serotonin 5-HT1 receptor.
Overall, these results suggested broad pharamacological
profile of Dimebon.
Discussion
Dimebon demonstrated significant positive effects in
phase II AD clinical trial conducted by Medivation in Rus-
sia [8]. It has also demonstrated efficacy in a phase 2 trial
of patients with Huntington's disease (HD) conducted by
Medivation and Huntington Study Group (DIMOND).
Despite extremely encouraging results in clinical trials, the
mechanisms responsible for the beneficial actions of
Dimebon in AD and HD remain poorly understood. Here,
we evaluated neuroprotective effects of Dimebon in a pre-
viously developed cellular model of HD [12]. We also
tested the ability of Dimebon to function as a "Ca2+ sign-
aling stabilizer" and an inhibitor of NMDAR and voltage-
gated Ca2+ channels in Ca2+ imaging and electrophysio-
logical experiments with wild type and YAC128 MSN cul-
tures. Consistent with the previous reports [9,10], we
found that Dimebon indeed inhibits NMDAR and volt-
age-gated Ca2+ channels. The IC50 for inhibitory actions
of Dimebon was equal to 10 μM for NMDAR and 50 μM
for voltage-gated Ca2+ channels in our experiments (Figs
3B and 4B). At 50 μM concentration, Dimebon also
exerted Ca2+  stabilizing and neuroprotective effects in
YAC128 MSN preparation (Figs 2G and 5C, Table 1). At
the concentration of 10 μM, Dimebon was not effective in
these in vitro assays (Figs 2G and 5B, Table 1). Similar effi-
cacy of Dimebon was observed in experiments with the
Drosophila model of HD [19]. Consistent with our find-
ings, neuroprotective effects of Dimebon in the Drosophila
model of HD were observed in the 50 – 100 μM concen-
tration range [19]. The protective effects of Dimebon in
the in vitro HD assay are in quantitative agreement with
the "Ca2+ stabilizing" effects of Dimebon (Fig 2G). Thus,
neuroprotective effects of Dimebon observed in our
experiments (Table 1, Fig 5C) most likely can be
explained by "Ca2+ stabilizing" effects of Dimebon result-
ing from inhibition of NMDAR (Fig 3) and voltage-gated
Ca2+ channels (Fig 4). It is also possible that Dimebon
exerts additional beneficial actions at the level of neuronal
mitochondria [11]. The concentration of Dimebon
required to inhibit mitochondrial permeability pore tran-
sition in isolated mitochondria was in the range of 50 μM
[11], the same concentration range as the neuroprotective
effects observed in our experiments with YAC128 MSN
cultures (Fig 5C, Table 1).
Using an identical experimental approach, in previous
studies we demonstrated that clinically relevant NMDAR
antagonist memantine (Namenda) was protective in the
YAC128 MSN glutamate toxicity assay at 10 μM concen-
tration [13]. Thus, Dimebon is 5-fold less effective than
memantine when tested in the in vitro HD model. We also
previously demonstrated that clinically relevant putative
mitochondrial permeability pore inhibitors Nortriptyline,
Desipramine, Trifluoperazine, and Maprotiline [20] were
also protective in YAC128 MSN toxicity assay at 2 μM con-
centration [12]. The Dimebon was 25-fold less effective
than these compounds when tested in the in vitro HD
model.
Unbiased evaluation of Dimebon against a set of bio-
chemical targets indicated that Dimebon efficiently inhib-
its  α-Adrenergic receptors (α1A,  α1B,  α1D, and α2A),
Histamine H1 and H2 receptors and Serotonin 5-HT2c, 5-
HT5A, 5-HT6 receptors with high affinity (Fig 6). Dimebon
also had significant effect on Dopamine D1, D2S, D3 recep-
tors, Imidazoline I2 receptor, Serotonin 5-HT2 and 5-HT2B
receptors (Fig 6). Interactions with these receptors need to
be taken into consideration in interpretation of results
obtained with Dimebon in HD and AD clinical trials.
Table 1: Effects of Dimebon on glutamate-induced apoptosis in WT and YAC128 MSN. 
WT (% TUNEL-positive) YAC128 (% TUNEL-positive)
Drug treatment 0 μM glutamate 250 μM glutamate 0 μM glutamate 250 μM glutamate
Dimebon
5 μM 7.53 ± 2.15 (7.25 ± 1.11)a 24.14 ± 3.22 (26.26 ± 3.50) 7.78 ± 1.29 (10.93 ± 2.89) 47.35 ± 1.95 (54.53 ± 5.40)
10 μM 8.34 ± 1.40 (5.88 ± 0.62) 39.58 ± 5.01 (37.59 ± 3.71) 7.86 ± 1.21 (7.24 ± 0.92) 54.90 ± 7.17 (65.84 ± 6.27)
50 μM 7.14 ± 1.19 (5.88 ± 0.62) 34.50 ± 2.12 (37.59 ± 3.71) 6.19 ± 0.96 (7.24 ± 0.92) 41.08 ± 3.25* (65.84 ± 6.27)
The fraction of apoptotic (TUNEL-positive) neurons is shown for wild type (WT) and YAC128 MSN without glutamate application and following 
application of 250 μM glutamate for 7 h. The experiments were conduced in the presence of 5, 10 and 50 μM Dimebon as indicated.
aThe number in parenthesis is the untreated control cells in the same batch of MSN culture.
*P < 0.05, compared with control cells and show protective effect.Molecular Neurodegeneration 2008, 3:15 http://www.molecularneurodegeneration.com/content/3/1/15
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Conclusion
From our results, we concluded that the "Ca2+ stabilizing"
effects of Dimebon may, in part, be responsible for the
clinical benefits observed in HD and AD trials. However,
50  μM concentration of Dimebon that is required to
achieve "Ca2+ stabilizing" and neuroprotective effects in
our experiments is not likely to be achieved in human tri-
als. In AD trials of Dimebon, the patients received 20 mg
pills [8], which should not lead to concentrations higher
than 0.6 μM assuming an ideal absorption and blood-
brain-barrier brain permeability profile. Thus, most bene-
ficial effects of Dimebon are likely to be due to its proper-
ties as a cognitive enhancer based on its ability to inhibit
H1 histamine receptors with IC50 = 3.4 nM [7]. It is also
Significant biochemical targets of Dimebon Figure 6
Significant biochemical targets of Dimebon. Significant biochemical targets of Dimebon are shown. The Cat numbers 
refer to the MDS Pharma Services assay specification. The receptors and species (human or rat) are listed. Dimebon was 
tested at 10 μM concentration. The % inhibition is shown for each receptor. Significant targets are defined as % inhibition > 
50%.Molecular Neurodegeneration 2008, 3:15 http://www.molecularneurodegeneration.com/content/3/1/15
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possible that Dimebon acts on novel high affinity targets
not present in cultured MSN preparation. Unbiased eval-
uation of Dimebon against a set of biochemical targets
indicated that Dimebon efficiently inhibits α-Adrenergic
receptors (α1A, α1B, α1D, and α2A), Histamine H1 and H2
receptors and Serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors
with high affinity. Dimebon also had significant effect on
Dopamine D1, D2S, D3 receptors, Imidazoline I2 receptor,
Serotonin 5-HT2 and 5-HT2B receptors. Potential interac-
tions with these receptors need to be taken into consider-
ation in interpretation of results obtained with Dimebon
in HD and AD clinical trials. Further evaluation of Dime-
bon in AD and HD whole animal models will be required
in order to better understand its mechanism of action.
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The results of Dimebon screening against a selected set of biochemical tar-
gets. The complete results obtained by MDS Pharma with a selected list of 
biochemical targets using 10 μM of Dimebon as a probe. The Cat numbers 
refer to the MDS Pharma Services assay specification. The receptors and 
species are listed. Dimebon was tested at 10 μM concentratio in duplicate. 
The % inhibition by Dimebon is shown numerically and graphically for 
each receptor. Significant targets (defined as % inhibition > 50%) are 
highlighted in yellow.
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